Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Liang, Tuoa | Chen, Jiaruia | Xu, Guoyonga | Zhang, Zidea | Xue, Jianga | Zeng, Haopenga | Jiang, Jiea | Chen, Tianyoua | Qin, Zhaojiea | Li, Haoa | Ye, Zhena | Nie, Yunfengb | Liu, Chonga | Zhan, Xinlia; *
Affiliations: [a] Department of Spine and Osteopathy Ward, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China | [b] Guangxi Medical University, Nanning, Guangxi, China
Correspondence: [*] Corresponding author: Xinli Zhan, Department of Spine and Osteopathy Ward, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, Guangxi, China. Fax: +86 771 5350021; E-mail: [email protected].
Abstract: BACKGROUND: Melanoma is fatal cancer originating from melanocytes, whose high metastatic potential leads to an extremely poor prognosis. OBJECTIVE: This study aimed to reveal the relationship among EMT, TIICs, and immune checkpoints in melanoma. METHODS: Gene expression data and clinical data of melanoma were downloaded from TCGA, UCSC Xena and GEO databases. EMT-related DEGs were detected for risk score calculation. “ESTIMATE” and “xCell” were used for estimating TIICs and obtaining 64 immune cell subtypes, respectively. Moreover, we evaluated the relationship between the risk score and immune cell subtypes and immune checkpoints. RESULTS: Seven EMT-related genes were selected to establish a risk scoring system because of their integrated prognostic relevance. The results of GSEA revealed that most of the gene sets focused on immune-related pathways in the low-risk score group. The risk score was significantly correlated with the xCell score of some TIICs, which significantly affected the prognosis of melanoma. Patients with a low-risk score may be associated with a better response to ICI therapy. CONCLUSION: The individualized risk score could effectively conduct risk stratification, overall survival prediction, ICI therapy prediction, and TME judgment for patients with melanoma, which would be conducive to patients’ precise treatment.
Keywords: EMT, TIICs, TME, biomarkers, immune checkpoints
DOI: 10.3233/CBM-210329
Journal: Cancer Biomarkers, vol. 34, no. 1, pp. 131-147, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]